for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Arena Pharmaceuticals, Inc.

ARNA.OQ

Latest Trade

48.70USD

Change

1.38(+2.92%)

Volume

73,043

Today's Range

47.31

 - 

49.08

52 Week Range

31.98

 - 

64.48

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
47.32
Open
47.31
Volume
73,043
3M AVG Volume
9.60
Today's High
49.08
Today's Low
47.31
52 Week High
64.48
52 Week Low
31.98
Shares Out (MIL)
49.83
Market Cap (MIL)
2,357.73
Forward P/E
5.67
Dividend (Yield %)
--

Next Event

Q3 2019 Arena Pharmaceuticals Inc Earnings Release

Latest Developments

More

Arena Pharmaceuticals Q2 Loss Per Share $1.24

Arena Pharmaceuticals Reports First Quarter 2019 Financial Results

Arena Pharmaceuticals Reports Fourth Quarter Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

Industry

Biotechnology & Drugs

Contact Info

6154 Nancy Ridge Dr

+1.858.4537200

http://www.arenapharm.com/

Executive Leadership

Tina Susan Nova

Independent Chairman of the Board

Amit D. Munshi

Director, President and Chief Executive Officer

Kevin R. Lind

Executive Vice President and Chief Financial Officer

Steven Wolf Spector

Executive Vice President, General Counsel and Secretary

Vincent E. Aurentz

Executive Vice President and Chief Business Officer

Key Stats

1.80 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.0K

2018

0.0K

2019(E)

0.8K
EPS (USD)

2016

-0.900

2017

-2.770

2018

-0.630

2019(E)

8.340
Price To Earnings (TTM)
4.09
Price To Sales (TTM)
2.90
Price To Book (MRQ)
1.96
Price To Cash Flow (TTM)
3.95
Total Debt To Equity (MRQ)
4.26
LT Debt To Equity (MRQ)
3.96
Return on Investment (TTM)
63.33
Return on Equity (TTM)
61.72

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up